News and Events
Learn more about current happenings at Ergomed.
Neil Clark Appointed Chief Executive Officer of PrimeVigilance
Stephen Stamp Appointed Chief Financial Officer of Ergomed
Guildford, UK – 11th January 2016: Ergomed plc, (LSE: ERGO) a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announced that Neil Clark, current Chief Financial Officer (CFO) has been appointed as full time Chief Executive Officer (CEO) of Ergomed’s trading subsidiary PrimeVigilance, the leading provider of drug safety and medical information services to the pharma and biotech industry. Neil remains an Ergomed plc Board member. As a consequence of this change the Board of Ergomed is pleased to announce that Stephen Stamp has been appointed as CFO and will join the Ergomed plc Board of Directors immediately.
Stephen Stamp brings to Ergomed more than 30 years of experience in corporate finance and general management in both public and private companies in the UK and the USA. Stephen joins Ergomed from US-based AssureRx Health, Inc, a personalised medicine and bio-informatics company where he was CFO. Prior to this he was CFO of EZCORP, Inc. (NASDAQ:EZPW), a consumer financial services company and Chief Operating Officer and CFO at Xanodyne Pharmaceuticals, Inc, a specialty pharmaceutical company.
Stephen has substantial experience working in UK-listed companies. He was Group Finance Director at Regus Plc (LSE:RGU) where he successfully listed the Company on London Stock Exchange Main Market and NASDAQ in October 2000. Prior to this he was Group Finance Director at Shire Pharmaceuticals (LSE:SHP, NASDAQ:SHPG) where he led the IPO on London Stock Exchange as well as a number of major acquisitions and financings. During his time at the Company, Shire’s market capitalisation increased from GBP20 million to GBP3.1 billion. Earlier in his career, Stephen was an investment banker with Lazard in London, advising mainly public companies on cross-border M&A and corporate finance. Prior to Lazard, he worked for KPMG in London where he qualified as a Chartered Accountant.
Dr Miroslav Reljanovic, Founder and CEO of Ergomed Plc, said: “We are pleased to strengthen the Board and I welcome Stephen to Ergomed as our new Chief Financial Officer. He brings significant experience and a track record of delivery in senior financial roles in the pharmaceutical industry. At the same time we will continue to benefit from Neil’s continued commitment to the Group as he takes over as full time CEO at PrimeVigilance.
“PrimeVigilance has grown into one of the leading European pharmacovigilance companies within five years and is a key growth driver for Ergomed. Neil’s leadership will enable us to expand and further strengthen our presence in the fast growing pharmaceutical post-marketing services sector.”
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Stephen Stamp, aged 54 years, has been a director of the following companies during the five years preceding the date of this announcement:
EUSA Pharma, Inc.
There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
For further information, please contact:
Hume Brophy – for UK enquiries
Mary Clark, Supriya Mathur and Hollie Vile
Tel: + 44 203 440 5654
NOMAD/Broker to the Company
Jonathan Senior, Stewart Wallace and Ben Maddison
Tel: +44 207 710 7600
MC Services – for Continental European enquiries
Tel: +49 211 529252 22
About Ergomed plc
Founded in 1997, Ergomed plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 40 countries.
Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical and generics companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has wide therapeutic expertise, with a particular focus in oncology, neurology and immunology and the development of orphan drugs. Ergomed’sapproach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies. Here Ergomed shares the risks and rewards of drug development, leveraging its expertise and services in return for carried interest in the drugs under development. – a low risk investment model for potential high returns. For further information, visit: https://www.ergomedplc.com.
Global pharmacovigilance and medical information services are provided through its group company PrimeVigilance. www.primevigilance.com
The pharmacovigilance services offered by PrimeVigilance support essential regulatory and scientific elements required to obtain and maintain a product license within Europe. This includes Qualified Persons, a compliant PV System with robust Quality Management, consistent Adverse Event data capture, expedited reporting, literature screening, preparation of Periodic Safety Update Reports, signal detection and evaluation, benefit-risk assessment, Risk Management Planning, compliance auditing, support during crisis and ad hoc consulting assignments. PrimeVigilance also offers a multi-language Medical Information service. PrimeVigilance has grown organically since 2008 and now has approximately 140 staff employed in its main offices in Guildford UK, and Zagreb, Croatia, as well as an international network of consultants. PrimeVigilance is currently providing services across more than 100 countries.
For more information please visit www.primevigilance.com
Forward Looking Statements
Certain statements contained within the announcement are forward looking statements and are based on current expectations, estimates and projections about the potential returns of Ergomed plc (“Ergomed”) and industry and markets in which Ergomed operates, the Directors’ beliefs and assumptions made by the Directors. Words such as “expects”, “anticipates”, “should”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “pipeline” and variations of such words and similar expressions are intended to identify such forward looking statements and expectations. These statements are not guarantees of future performance or the ability to identify and consummate investments and involve certain risks, uncertainties, outcomes of negotiations and due diligence and assumptions that are difficult to predict, qualify or quantify. Therefore, actual outcomes and results may differ materially from what is expressed in such forward looking statements or expectations. Among the factors that could cause actual results to differ materially are: the general economic climate, competition, interest rate levels, loss of key personnel, the result of legal and commercial due diligence, the availability of financing on acceptable terms and changes in the legal or regulatory environment.
These forward-looking statements speak only as of the date of this announcement. Ergomed expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in Ergomed’s expectations with regard thereto, any new information or any change in events, conditions or circumstances on which any such statements are based, unless required to do so by law or any appropriate regulatory authority